A Study of Cardiovascular Events iN Diabetes Plus (ASCEND PLUS)

niversity of Oxford0 个研究点目标入组 20,000 人开始时间: 2022年6月27日最近更新: 2023年3月27日

试验速览

暂无简介。

•1. Myocardial Infarction
•3. Current or planned treatment with a GLP-1 RA
•4. Previous hypersensitivity to or intolerance of GLP-1 RA therapy
•5. Severe hypoglycaemia within the last six months or during run-in
•6. Symptomatic hypoglycaemia within the last month
•7. Currently under consideration to commence insulin
•8. Severe heart failure (NYHA class 4)
•9. Current or planned renal replacement therapy
•10. Unwilling to complete regular follow-up assessments
•11. Ongoing treatment for cancer or diagnosis with cancer (excluding non-melanoma skin cancer) in the last 2 years
•12. Type 1 or other type of diabetes (e.g. MODY)
•13. History of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma
•14. Currently breastfeeding or pregnant, or planning a pregnancy
•15. Any serious illness which is likely to limit survival or active participation for at least 5 years
•16. Current participation in a clinical trial with an unlicensed investigational medicinal product used to treat diabetes
•17. For participants taking thyroxine, lack of agreement to arrange a thyroid function test in the next 3 months and agree to regular testing throughout the trial
•18. Non-adherence to run-in treatment (i.e. reports taking the run-in tablets ‘Never’ or ‘Only occasionally’
•19. Their doctor does not wish them to be randomised

发起方